

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

8

Application Number 10/511,531

Filing Date 10/15/2004

First Named Inventor K. TAKASHIMA

Art Unit tba

Examiner Name tba


Attorney Docket Number 3041 USOP

**ENCLOSURES (Check all that apply)**


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Certificate of Express Mailing
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Forms PTO/SB/08A and SB/08B
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	Cited References (11)
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b>	

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Takeda Pharmaceuticals North America, Inc.		
Signature			
Printed name	Mark Chao		
Date	1/11/05	Reg. No.	37,293

**CERTIFICATE OF TRANSMISSION/MAILING**I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: **EXPRESS**

Signature			
Typed or printed name	Gail L. Winokur	Date	1/12/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No. EV524907031 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/511,531  
Filed: October 15, 2004  
1<sup>st</sup> Inventor: Katsunori TAKASHIMA  
For: Preventives for HIV Infection  
Atty. Dkt. No. 3041 USOP

Art Unit: tba  
Examiner: tba  
Allowed:  
Batch:  
Paper No.: #3

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524907031 US

DATE IN: January 12, 2005

**Itemized Papers/Items:**


1. This Certificate of Express Mailing and Return Postcard (2 pages)
2. Transmittal Form (1 page X 2)
3. Information Disclosure Statement (1 page) with Forms PTO SB/08A and SB/08B (3 pages), and cited references (11)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PGT  
Commissioner for Patents  
P.O. BOX 1450  
Arlington, VA 22313-1450

on this date, 1/12/05

Dated: 1/12/05

  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/511,531  
Filed: October 15, 2004  
1<sup>st</sup> Inventor: Katsunori TAKASHIMA  
For: Preventives for HIV Infection  
Atty. Dkt. No. 3041 USOP

Art Unit: tba  
Examiner: tba  
Allowed:  
Batch:  
Paper No.:

## Information Disclosure Statement

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Form PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.


Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated:

(847) 383-3372  
(847) 383-3391

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/511,531
		Filing Date	10/15/2004
		First Named Inventor	Katsunori TAKASHIMA
		Art Unit	tba
Examiner Name	tba		
Sheet 3	of 3	Attorney Docket Number	3041 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A10	MASANORI BABA, et al., "A Small-molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective Anti-HIV-1 Activity", Proc. Natl. Acad. Sci. USA, (1999), pp. 5698-5703, Vol. 96.	
	A11	MITSURU SHIRAISHI, et al., "Discovery of Novel, Potent, and Selective Small-molecule CCR% Antagonists as Anti-HIV-1 Agent: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety", J. Med. Chem., (2000), pp. 2049-2063, Vol. 43.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.